- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07371338
파킨슨병 환자에서 IPS101A의 안전성, 효능 및 약동학을 평가하는 1상 임상시험
도즈-에스컬레이션, 싱글-센터, 오픈-라벨 페이즈 1 임상 시험: 파킨슨병 환자(호엔-야 4-5단계, 10년 이상 진단, 모든 가능한 단일 요법 또는 병합 요법으로 조절되지 않음)에서 아데노-연관 바이러스(AAV) 유전자 치료 제품 IPS101A의 안전성, 효능 및 약동학 평가
The purpose of this study is to evaluate the dose-related safety and tolerability of IPS101A, an adeno-associated virus (AAV) gene therapy, in patients with Parkinson's disease who exhibit severe functional impairment corresponding to Hoehn & Yahr stages 4-5 and whose symptoms are not adequately controlled despite all available monotherapy and combination therapy options. In addition, the study aims to assess the maximum tolerated dose (MTD) of IPS101A, as well as its preliminary efficacy and pharmacokinetic (PK) characteristics.
연구 개요
연구 유형
등록 (추정된)
단계
- 1단계
연락처 및 위치
연구 연락처
- 이름: ChoLong Park
- 전화번호: +82-2-3499-4266
- 이메일: clpark@innopeutics.com
연구 연락처 백업
- 이름: Tae-gyun Kim
- 이메일: contact@innopeutics.com
연구 장소
-
-
-
Seoul, 대한민국
- 모병
- Severance Hospital
-
연락하다:
- Professor, MD, PhD
- 이메일: phlee@yuhs.ac
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subjects who have a diagnosis of Parkinson's disease that meets the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria at the time of the Screening Visit.
- Male or female subjects aged 50 to 80 years (inclusive) at the time of providing written informed consent, with a documented diagnosis of Parkinson's disease.
- Subjects with a duration of Parkinson's disease of at least 10 years prior to the Screening Visit, based on medical history and/or medical records.
- Subjects with Parkinson's disease that is inadequately controlled despite all available standard-of-care treatments, including monotherapy or combination therapy, as determined by the Investigator.
- Subjects with a Hoehn & Yahr stage of 4 or 5 in the off state at the Screening Visit.
Exclusion Criteria:
- Subjects with Parkinson's disease dementia (PDD) who meet the diagnostic criteria established by the Movement Disorder Society (MDS) Task Force, as determined by the Investigator at Screening.
- Subjects with a Korean Mini-Mental State Examination (K-MMSE) score ≤ 24 at the Screening assessment.
- Subjects in whom imaging findings suggestive of Parkinsonism-plus syndrome are observed on PET and MRI performed at the Screening Visit, as assessed by the Investigator and/or a qualified imaging specialist.
- Subjects who do not meet the diagnostic criteria for Parkinson's disease dementia but present with major visual hallucinations, as judged by the Investigator.
- Subjects with drug-induced parkinsonism, confirmed by clinical history and/or medical records, and determined by the Investigator.
- Subjects who are judged by the investigator to be unsuitable for participation in this clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low dose (1.0 x 10^10 vg/patient)
IPS101A |
The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side. |
|
실험적: High dose(2.0 x 10^10 vg/patient)
IPS101A |
The investigational product (IP) will be administered as a single dose. All subjects will receive stereotactic injections into the left and right substantia nigra of the midbrain, with one administration per side. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety Evaluation: dose-limiting toxicity (DLT)
기간: Baseline to Week 8
|
Frequency and proportion of subjects who developed dose-limiting toxicity (DLT) |
Baseline to Week 8
|
|
Safety Evaluation: Severity and frequency of reported adverse events
기간: Baseline to Week 52
|
Assess severity and frequency of reported adverse events |
Baseline to Week 52
|
|
Safety Evaluation: clinically-relevant changes in laboratory testing assessed by medical personnel
기간: Baseline to Week 52
|
The clinical significance of laboratory test results after administration of a clinical trial drug is confirmed by comparing them with those before administration. |
Baseline to Week 52
|
|
Safety Evaluation: clinically-relevant changes in physical exams assessed by medical personnel
기간: Baseline to Week 52
|
The results of the physical examination after administration of the clinical trial drug are compared with those before administration to determine whether clinically significant symptoms occur. |
Baseline to Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change from Baseline in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores (defined on/off)
기간: Baseline to Weeks 4, 12, 24, 36, and 52.
|
Each symptom is rated on a scale of 0 to 4, with higher scores indicating more severe Parkinson's disease. |
Baseline to Weeks 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Hoehn & Yahr stage (defined on/off)
기간: Weeks 1, 4, 12, 24, 36, and 52.
|
This scale is classified from 0 to 5, with a higher score indicating a more severe degree of Parkinson's disease. |
Weeks 1, 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Non-Motor Symptoms Scale for Parkinson's Disease (NMSS)
기간: Weeks 4, 12, 24, 36, and 52.
|
This scale is rated on a scale of severity (0-3 points) and frequency (1-4 points). A higher score indicates more severe Parkinson's disease. |
Weeks 4, 12, 24, 36, and 52.
|
|
Change from Baseline in Parkinson's Disease Questionnaire (PDQ-39) scores
기간: Weeks 4, 12, 24, 36, and 52
|
The scale consists of 800 points, and a higher score indicates a lower quality of life. |
Weeks 4, 12, 24, 36, and 52
|
|
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-CSF
기간: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
|
Distribution evaluation of IPS101A (AAV9 vector distribution evaluation)-blood
기간: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
|
Evaluation of humoral (anti-AAV9 antibodies) and cellular (IFN-γ activity) immune responses to AAV9
기간: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using ELISA |
Baseline to Week 52
|
|
Assessment of AAV9 shedding in biological specimens-urine
기간: Baseline to Week 52
|
After IP administration, the detection of AAV genome was measured using q-PCR. |
Baseline to Week 52
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .